Validated water treatment solutions for pharmaceutical manufacturing with GMP-compliant equipment and comprehensive documentation.
Treat high-COD pharmaceutical wastewater with strong organic loads.
Wastewater treatment for pharmaceutical formulation plants. Handle excipients, cleaning agents and product residues.
Treat biopharmaceutical wastewater from fermentation and cell culture.
GMP-compliant wastewater treatment for pharmaceutical facilities.
Water Management for Pharmaceutical Operations
Pharmaceutical manufacturing generates wastewater containing active pharmaceutical ingredients (APIs), solvents, and high organic loads. Our treatment solutions are designed to meet stringent regulatory requirements with validated equipment, comprehensive documentation, and GMP-compliant construction. API residues and solvents are often toxic and poorly biodegradable, so advanced oxidation, stripping and activated-carbon polishing are designed in alongside biological treatment. Reynolds & Bauhm deliver validated, fully documented, GMP-compliant plants that satisfy both discharge consent and pharmaceutical quality regimes.
Advanced treatment processes for removing active pharmaceutical ingredients from manufacturing wastewater to prevent environmental contamination.
Explore Pharma Api RemovalBiological and chemical conditioning and treatment systems engineered to handle the high COD and BOD typical of pharmaceutical fermentation and synthesis operations.
Explore Pharma High OrganicEquipment designed and documented to Good Manufacturing Practice standards with full traceability, validation support, and IQ/OQ documentation.
GMP ComplianceComprehensive documentation package including material certificates, welding records, surface finish reports, and validation support documentation.
Explore Pharma DocumentationPharmaceutical Sectors We Serve
Wastewater treatment for active pharmaceutical ingredient production including chemical synthesis, fermentation, and extraction processes.
Explore Pharma Api ManufacturingTreatment of wash waters and cleaning effluents from tablet, capsule, and liquid formulation operations.
Explore Pharma FormulationSpecialised treatment for biologics manufacturing including cell culture, protein purification, and viral processing wastewater.
Explore Pharma BiopharmaWater treatment for injectable and sterile product facilities with validated systems and comprehensive monitoring.
Explore Pharma SterileFlexible treatment solutions for research and development operations with varying waste streams and batch processes.
Explore Pharma RdRobust treatment systems for CDMO facilities handling multiple products with diverse wastewater characteristics.
Explore Pharma ContractStream chemistry by manufacturing process — from fermentation through CIP to final discharge
| Source | BOD (mg/L) | COD (mg/L) | TSS (mg/L) | pH | Key Contaminants |
|---|---|---|---|---|---|
| API chemical synthesis | 500 – 3,000 | 2,000 – 30,000 | 200 – 2,000 | 1 – 13 | Solvents (DCM, MeOH, IPA, DMF, THF), strong acids/bases, halogenated intermediates, residual APIs <1–1,000 µg/L |
| Fermentation broth waste | 5,000 – 25,000 | 10,000 – 80,000 | 2,000 – 20,000 | 4 – 8 | Mycelial biomass, residual nutrients, antibiotics 10–1,000 mg/L, surfactants |
| Tablet / solid-dose formulation | 200 – 800 | 500 – 2,500 | 100 – 600 | 6 – 9 | Excipients (lactose, starch, MCC), binders, dust filtrate, API residues |
| Sterile / liquid formulation | 50 – 400 | 200 – 1,500 | 20 – 200 | 5 – 9 | WFI-grade losses, preservatives, low organic load |
| Biopharma cell-culture waste | 1,000 – 5,000 | 3,000 – 15,000 | 500 – 3,000 | 6.5 – 7.5 | Spent media (glucose, glutamine), serum, BSA, residual cell debris, low-level mAb/protein |
| CIP / SIP rinse water | 100 – 600 | 300 – 1,500 | 50 – 300 | 2 – 13 (cycled) | NaOH, HNO3/H3PO4, surfactants, residual product |
| Lab / R&D wash water | variable | 50 – 5,000 | 10 – 500 | 2 – 12 | Mixed solvents, trace APIs, glassware rinses, biological waste |
| Sanitary domestic blend | 150 – 400 | 300 – 800 | 100 – 400 | 6.5 – 8 | Standard sewage from staff facilities |
EU PNEC values for common APIs (e.g. diclofenac 0.05 µg/L, sulfamethoxazole 0.6 µg/L, ethinylestradiol 0.035 ng/L) increasingly drive site discharge limits. Persistent compounds (carbamazepine, fluoroquinolones) require advanced oxidation or GAC polishing beyond conventional biological treatment.
Multi-Stage Approach
Screening to remove solids and protect downstream equipment from debris in manufacturing effluents.
Flow and load balancing to handle batch discharges and varying wastewater characteristics from pharmaceutical production.
Activated carbon filtration and polishing to remove residual APIs and meet discharge standards.
Products for Pharmaceutical Applications
Membrane bioreactors combining advanced biological treatment with membrane filtration for high-quality effluent suitable for sensitive discharge environments.
Benefit: Superior effluent quality, small footprint
Ozonation and UV systems for degrading recalcitrant pharmaceutical compounds and APIs that resist conventional advanced biological treatment.
Benefit: Effective API destruction
High-efficiency clarification for removing precipitated solids and chemical floc with validated performance and documentation.
Benefit: Compact, validated design
Granular activated carbon filters for adsorption of residual pharmaceuticals, solvents, and organic compounds.
Benefit: Effective API removal
Multi-disc screw presses for pharmaceutical sludge with stainless steel construction and clean-in-place capability.
Benefit: Sanitary design, low energy
Automated control systems with comprehensive data logging for regulatory compliance and process validation.
Benefit: Full traceability, 21 CFR Part 11 ready
Operational, Environmental & Economic Advantages
Explore Other Industries We Serve
Contact our experts for GMP-compliant solutions with full validation support.
Our expertise spans multiple industries with sector-specific water treatment solutions.